We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current REPCF market cap is 65k. The company's latest EPS is CAD -0.0048 and P/E is -2.08.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 252k | 353k | 354k | 353k | 353k |
| Operating Income | -3.02M | -1.35M | -2.3M | -1.4M | -1.39M |
| Net Income | -2.95M | -1.58M | -4.07M | -743k | -311k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 419k | 420k | 592k | 798k | 287k |
| Total Liabilities | 3.35M | 5.48M | 7.44M | 6.71M | 4.82M |
| Total Equity | -2.93M | -5.06M | -6.84M | -5.92M | -4.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -2.78M | -765k | -2.51M | -1.41M | -1.42M |
| Investing | -29k | 11k | N/A | N/A | N/A |
| Financing | 416k | 764k | 2.7M | 1.6M | 1.06M |
| Market Cap | 65k |
| Price to Earnings Ratio | -2.08 |
| Price to Sales Ratio | 1.85 |
| Price to Cash Ratio | 11.11 |
| Price to Book Ratio | -0.14 |
| Dividend Yield | - |
| Shares Outstanding | 65M |
| Average Volume (1 week) | 7.79k |
| Average Volume (1 Month) | 9.92k |
| 52 Week Change | -98.00% |
| 52 Week High | 0.065 |
| 52 Week Low | 0.000001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | RepliCel Life Sciences Inc (CE) |
| Address |
900 - 570 granville street vancouver, british columbia V6C 3P1 |
| Website | https://www.replicel.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
